You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR PROSTIN F2 ALPHA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PROSTIN F2 ALPHA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00141895 ↗ A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death Terminated American University of Beirut Medical Center Phase 3 2004-09-01 Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance to effect the medical termination of pregnancy in the second trimester, either alone or after pretreatment with mifepristone. The primary reasons for this prompt incorporation into standard practice include its low cost and the lack of stringent storage requirements. Vaginal administration seems to be more efficacious than when given orally. The use of sublingual misoprostol for first trimester abortions has been extensively investigated as evidenced by the large number of publications comparing sublingual to other routes of misoprostol for first trimester pregnancy termination, on the assumption that the sublingual route would have a similar efficacy of the vaginal route. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the second trimester termination following intrauterine fetal death. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.
NCT00545194 ↗ Cervical Ripening Before Induction of Labour at Term: a Randomised Comparison of Prostin vs Propess Completed Institut National de la Santé Et de la Recherche Médicale, France Phase 3 2002-01-01 The aim of this study is to compare two different preparation
NCT01635439 ↗ Prostin and Propess in Induction of Labor Completed North West Armed Forces Hospital Phase 3 2010-12-01 The purpose of the study was to compare the safety and efficacy of two agents used in induction of labor Propess (Controlled release dinoprostone, PGE2, pessary) and Prostin E2 (Dinoprostone vaginal Tablet).
NCT01635439 ↗ Prostin and Propess in Induction of Labor Completed Ain Shams University Phase 3 2010-12-01 The purpose of the study was to compare the safety and efficacy of two agents used in induction of labor Propess (Controlled release dinoprostone, PGE2, pessary) and Prostin E2 (Dinoprostone vaginal Tablet).
NCT02620215 ↗ Cervical Ripening Balloon in Induction of Labour at Term Completed University of Malaya Phase 4 2015-11-01 About 1 in 6 deliveries in KKH are induced with prostaglandins. Inpatient induction can be a lengthy process especially when cervical priming is required. Although mechanical method of induction of labour (IOL) is established, its use in Singapore is uncommon. Systematic reviews comparing mechanical method against pharmacological and surgical IOL showed that mechanical method has similar efficacy with lower risk profile. As IOL is a common obstetric procedure, a revisit on the techniques is warranted. A multi-centre randomised controlled trial concluded that both cervical ripening balloon and prostaglandin are effective and complementary methods for IOL in uncomplicated singleton pregnancies, but did not examined the effects of pain. The investigators propose to evaluate the adverse events in the 12 hours after CRB or 1st prostaglandin insertion, its efficiency in term singleton IOL in Singapore context and test the acceptability of women in Singapore in using the CRB as an alternative method of induction of labour while using a non-incremental balloon filling regime. Currently, there is no efficient method of induction that can be used safely in an outpatient setting. Through this study, the investigators hope to show that there are no major adverse events in the 12h after patients are induced with CRB, this potentially supports outpatient IOL with CRB which can reduce hospitalisation and medical costs. A non-incremental balloon filling regime will decrease time delays and may increase patient satisfaction during its use in induction of labour.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PROSTIN F2 ALPHA

Condition Name

Condition Name for PROSTIN F2 ALPHA
Intervention Trials
IUCD Complication 2
Cervical Ripening 1
Labor Pain 1
Cesarean Section; Dehiscence 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PROSTIN F2 ALPHA
Intervention Trials
Stillbirth 1
Fetal Death 1
Rupture 1
Fetal Membranes, Premature Rupture 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PROSTIN F2 ALPHA

Trials by Country

Trials by Country for PROSTIN F2 ALPHA
Location Trials
Egypt 3
Singapore 2
Lebanon 1
Croatia 1
Saudi Arabia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PROSTIN F2 ALPHA

Clinical Trial Phase

Clinical Trial Phase for PROSTIN F2 ALPHA
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PROSTIN F2 ALPHA
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 3
Recruiting 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PROSTIN F2 ALPHA

Sponsor Name

Sponsor Name for PROSTIN F2 ALPHA
Sponsor Trials
Aswan University Hospital 3
University Medical Centre Maribor 1
Medicem International 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PROSTIN F2 ALPHA
Sponsor Trials
Other 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.